Track topics on Twitter Track topics that are important to you
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One 's Bill Mann consider how much worse Teva Pharmaceutical Industries looks presently, after a second quarter report that featured weak sales, low profits, a 75% dividend cut, and -- to top it off -- a guidance reduction. The key difficulty for the company is that it's carrying too much debt for its size, amid an environment where its income is shrinking -- not a tenable position.
Original Article: Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad YearNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...